Zhejiang Starry PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 2/6
Zhejiang Starry PharmaceuticalLtd has a total shareholder equity of CN¥2.7B and total debt of CN¥2.6B, which brings its debt-to-equity ratio to 96.5%. Its total assets and total liabilities are CN¥5.9B and CN¥3.2B respectively. Zhejiang Starry PharmaceuticalLtd's EBIT is CN¥127.1M making its interest coverage ratio 1.5. It has cash and short-term investments of CN¥686.2M.
Key information
96.5%
Debt to equity ratio
CN¥2.58b
Debt
| Interest coverage ratio | 1.5x |
| Cash | CN¥686.23m |
| Equity | CN¥2.67b |
| Total liabilities | CN¥3.20b |
| Total assets | CN¥5.88b |
Recent financial health updates
Recent updates
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues
Sep 30
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality
May 06Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost
Mar 12Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?
Feb 28Financial Position Analysis
Short Term Liabilities: 603520's short term assets (CN¥2.3B) do not cover its short term liabilities (CN¥2.6B).
Long Term Liabilities: 603520's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥616.2M).
Debt to Equity History and Analysis
Debt Level: 603520's net debt to equity ratio (70.9%) is considered high.
Reducing Debt: 603520's debt to equity ratio has reduced from 199.7% to 96.5% over the past 5 years.
Debt Coverage: 603520's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 603520's interest payments on its debt are not well covered by EBIT (1.5x coverage).